Dijon

• Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free … Ended recruitment
  2024-516198-61-00 5 2013-06-05 Patients with high risk of relapse, ER+ and HER2- primary non-metastat
• Chemotherapy or chemotherapy + hormonotherapy in women over 70 with HER2 receptor-negative but estrogen receptor-positive breast cancer acco … Ended recruitment
  2024-516996-34-00 5 2012-04-12 oestrogen-receptor (ER)-positive HER2-negative breast carcinoma
• An Extension Study of trastuzumab emtansine administered as a single agent or in combination with other anti-cancer therapies in patients pr … Ended recruitment
  2023-503479-79-00 4 2011-06-17 Metastatic Cancer
• RB SFCE 2009 : Adjuvant treatment in extensive unilateral retinoblastoma primary enucleated Ended recruitment
  2024-514844-10-00 4 2010-03-18 Retinoblastoma
• Treatment protocol for osteosarcomas in children, adolescents and adults including a randomized trial and biological studies Ended recruitment
  2024-514756-32-00 5 2007-03-19 High grade osteosarcoma
• Phase 2a study to assess the efficacy and safety of GIA632 in adult participants with moderate to severe atopic dermatitis Halted
  2025-521503-43-00 4 2026-02-12 Atopic dermatitis
• Public title :A Phase 1b/2a trial to evaluate Invobenitug also known as Procizumab (PCZ; AK1967) in critical cardiovascular care. Halted
  2024-518450-16-00 9 2025-06-13 Cardiogenic shock due to Acute Coronary Syndrome, cardiogenic shock of
• Salvage Therapy for Patients with Inadequate Response to Standard of Care Therapy in Granulomatosis with Polyangiitis Halted
  2024-516687-28-00 5 2025-06-06 Patients with GPA and inadequate response to standard of care therapy
• BLOCKADE OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN PATIENTS WITH ARVD.BRAVE Halted
  2023-505048-20-00 4 2024-12-20 Arrhythmogenic right ventricular dysplasia
• A study to evaluate novel immunotherapy combinations in participants with advanced non-small cell lung cancer (NSCLC) Halted
  2023-508730-34-00 9 2024-07-10 Non-small cell lung cancer (NSCLC): - Locally advanced NSCLC where par
• Phase 2 Study of CAL02 plus Standard of Care in Severe Community-Acquired Bacterial Pneumonia (SCABP) Halted
  2022-502049-91-00 4 2023-09-26 SEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (SCABP)
• MIVAR - Milrinone Infusion for VAsospam treatment in subarachnoid hemoRrhage Ended
  2024-515994-83-00 5 2026-01-13 aneurysmal subarachnoid hemorrhage with a vasospasm
• AKTive-001: A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients with Advanced Solid Tumors with AKT1 E17K Mutation Ended
  2024-515391-12-00 1 2025-03-15 Advanced Solid Tumors with AKT1 E17K Mutation
• Study evaluating the efficacy of the treatment after targeting PD-L1 and TIGIT in tumors with tertiary lymphoid structures Ended
  2023-503218-56-00 4 2025-01-30 Adult patients with a histologically confirmed TLS-positive advanced o
• Efficacy of tocilizumab in the treatment of acute anterior ischemic optic neuropathy optic neuropathy in Horton's disease Ended
  2024-519977-20-00 4 2025-01-27 Acute Anterior Ischemic Optic Neuropathy associated with Giant Cell Ar
• A clinical study of sotatercept in people with pulmonary arterial hypertension (MK-7962-024) Ended
  2024-512278-92-00 4 2024-12-09 Pulmonary Arterial Hypertension (PAH)
• Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures – SHIN … Ended
  2023-508812-45-00 10 2024-11-11 Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures
• SCLERITA - Safety and efficacy of itacitinib in adults with systemic sclerosis: a phase II, randomized, controlled trial Ended
  2024-513648-27-00 4 2024-10-25 Patients with newly or active diffuse Systemic sclerosis (SSc) at the
• Impact of 18F-FES TEP on therapeutical management in patients with metastatic breast cancer, ER positive and HER2 negative, in relapse after … Ended
  2024-517400-11-00 6 2024-10-24 Patients with metastatic breast cancer initially presenting with overe
• A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended
  2024-511363-28-00 5 2024-09-24 hidradenitis suppurativa (HS)
• Perioperative Treatment in Resectable Gastric Cancer with Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, … Ended
  2024-516299-13-00 4 2024-09-06 Resectable Gastric Cancer
• SPARTANA : Spartalizumab, mDCF (docetaxel, cisplatin and 5-fluorouracil) and radiotherapy in patients with metastatic squamous cell anal car … Ended
  2024-516005-23-00 4 2024-08-22 metastatic squamous cell anal carcinoma
• An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budig … Ended
  2023-508356-19-00 4 2024-06-25 Pancreatic adenocarcinoma metastatic
• EMPIRE : Targeting MDM2 and PD1 in tumors with tertiary lymphoid structures Ended
  2023-506823-28-00 4 2024-06-14 Adult patients with locally advanced/metastatic solid tumors

Showing 673–696 of 825 trials